Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
06/05/2025 14:28
May 6 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O: HEPION PHARMACEUTICALS - ON APRIL 30, ENTERED INTO BINDING LOI IN-LICENSES DIAGNOSTIC TESTS FROM NEW DAY DIAGNOSTICS - SEC FILING HEPION PHARMACEUTICALS INC - TO PAY $525,000 CASH AND $200,000 IN STOCK TO NEW DAY - SEC FILING HEPION PHARMACEUTICALS INC - AGREES TO PAY UP TO $17.15 MILLION UPON MILESTONE ACHIEVEMENT - SEC FILING HEPION PHARMACEUTICALS INC - TO PAY ROYALTIES IN UPPER SINGLE TO LOW DOUBLE DIGITS BASED ON NET SALES- SEC FILING Source text: [ID:n0001641172-25-008761] Further company coverage: HEPA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement